The activation and deactivation of apoptosis is a promising field of research in basic biomedical research. The team led by Prof. Franz Hagn from the Chair of Structural Membrane Biochemistry at the TUM School of Natural Sciences has now discovered a new switch: "Many research teams worldwide are working on the exciting topic of apoptosis and its targeted control. The big advantage is that we are dealing with a highly efficient, evolutionarily developed regulatory mechanism. So, we don't have to invent something completely new, but can use the appropriate structural methods to learn from nature's optimized processes."

A comprehensive review in "Biofunct. Mater." meticulously details the most recent advancements and clinical translation of intelligent nanodrugs for breast cancer treatment. This paper presents an exhaustive overview of subtype-specific nanostrategies, the clinical benefits of FDA-approved nanodrugs, and innovative approaches to address tumor heterogeneity and treatment resistance. This serves as a foundational framework and pragmatic guide for enhancing precision-based breast cancer therapies.

In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin cancer, and identified two mutated tumor proteins, or neoantigens, that contain features of good candidates for a vaccine. At the same time, they used artificial intelligence to create 3D models to help them understand and predict which neoantigens could provoke T cells, a type of white blood cell critical to the immune system, to attack the cancer.

Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found.

The observation by researchers at the University of Florida and the University of Texas MD Anderson Cancer Center is a defining moment in a decade-plus of research testing mRNA-based therapeutics designed to "wake up" the immune system against cancer.

About one-third of all drugs approved by the Food and Drug Administration target the largest family of cell membrane receptors called G protein-coupled receptors (GPCRs).

GPCRs are indispensable for maintaining human health as they play a role in nearly every physiological function. These receptors are embedded in the membranes of cells and detect a wide variety of biological signaling molecules arriving outside the cell.

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary human T cells, addressing a key manufacturing and scalability challenge in next-generation cell therapies. The research, published October 21, 2025, in Nature Biotechnology, demonstrates how CRISPRoff and CRISPRon can reprogram a patient’s own T cells for therapeutic purposes without the cell toxicity and DNA damage associated with traditional gene editing approaches.

Estonia's obesity rate has been steadily climbing and so have scientific efforts to understand why. New study, published in Nature Communications, takes a closer look at the genes behind body weight and how they might point toward future treatments for obesity.

For decades, scientists have sought a single "obesity gene."